Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
124,428,941
-
Share change
-
-27,345,949
-
Total reported value
-
$67,025,039
-
Put/Call ratio
-
48%
-
Price per share
-
$0.5387
-
Number of holders
-
79
-
Value change
-
-$30,501,887
-
Number of buys
-
27
-
Number of sells
-
35
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q4 2024
As of 31 Dec 2024 Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) had 79 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 124,428,941 shares of stock of the company.
Largest 10 holders included EcoR1 Capital, LLC, Long Focus Capital Management, LLC, NEA Management Company, LLC, Two Seas Capital LP, BAILLIE GIFFORD & CO, MPM ASSET MANAGEMENT LLC, MPM BIOIMPACT LLC, PFM Health Sciences, LP, BANK OF AMERICA CORP /DE/, and RENAISSANCE TECHNOLOGIES LLC.
This table shows 79 institutional shareholders of the security as of 31 Dec 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.